Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 1;36(4):327-336.
doi: 10.1097/YCO.0000000000000871. Epub 2023 May 23.

The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry

Robert A Bittner  1   2 , Andreas Reif  1 , Mishal Qubad  1
Affiliations
Review

The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry

Robert A Bittner et al. Curr Opin Psychiatry. .

Abstract

Purpose of review: Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS). Although the evidence base for its wide-ranging, unique efficacy continues to expand, clozapine remains alarmingly underutilized in industrialized countries. Analyzing the causes and consequences of this problem is crucial for substantially improving the quality of care for TRS patients.

Recent findings: Clozapine is the most effective antipsychotic for reducing all-cause mortality in TRS. In most cases, treatment resistance emerges during the first psychotic episode. Delaying clozapine treatment has a negative impact on long-term outcome. Patients' experience with clozapine treatment is largely positive despite a comparatively high rate of side effects. Patients prefer clozapine, while psychiatrists regard it as a burden due to concerns regarding safety and side effect management. Shared decision-making (SDM), which increases the likelihood of a clozapine recommendation, is not routinely used, possibly due to stigmatization of TRS patients.

Summary: The mortality-reducing effects of clozapine alone warrant its regular use. Therefore, psychiatrists must not exclude patients from the decision regarding a clozapine trial by not even offering it. Rather, they have a clear obligation to align their actions more closely with the existing evidence and patients' needs and to facilitate the timely initiation of clozapine.

PubMed Disclaimer

References

    1. Spark DL, Fornito A, Langmead CJ, et al. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Translational Psychiatry 2022; 12:147.
    1. Kane JM, McEvoy JP, Correll CU, et al. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs 2021; 35:1189–1205.
    1. Rubio JM, Kane JM. How and when to use clozapine. Acta Psychiatr Scand 2020; 141:178–189.
    1. de Bartolomeis A, Vellucci L, Barone A, et al. Clozapine's multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. Pharmacol Ther 2022; 236:108236.
    1. Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand 2017; 136:37–51.

MeSH terms